Mereo BioPharma Reports $7M Net Loss in Q3 2025, Revenue of $500K for Nine Months

Mereo BioPharma Group plc reported its financial results for the third quarter of 2025, revealing a net loss of $7.0 million, a significant improvement compared to a net loss of $15.0 million in the same period last year. The company did not generate any revenue during the third quarter, but for the nine months ended September 30, 2025, it recorded revenue of $500,000, attributed to a milestone payment from its licensing agreement with ReproNovo. This marks a notable shift from the previous year, where no revenue was reported for the same period.

Operating expenses for the third quarter totaled $10.0 million, slightly higher than the $9.4 million reported in the prior year. Research and development expenses increased to $4.3 million from $3.2 million, primarily due to higher costs associated with the development of setrusumab and alvelestat. General and administrative expenses decreased marginally to $6.0 million from $6.2 million, reflecting lower professional fees. The company’s accumulated deficit as of September 30, 2025, stood at $493.7 million, indicating ongoing financial challenges as it continues to invest in its product pipeline.

In terms of strategic developments, Mereo BioPharma has focused on advancing its late-stage clinical product candidates, including setrusumab for osteogenesis imperfecta and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease. The company has also engaged in partnerships, such as the licensing agreement with ReproNovo, which has provided a pathway for milestone payments. As of September 30, 2025, Mereo had cash and cash equivalents of $48.7 million, which it expects will be sufficient to fund operations for at least the next twelve months.

Operationally, Mereo BioPharma has made progress in its clinical trials, with setrusumab receiving orphan designation from both the European Commission and the U.S. Food and Drug Administration. The company has also been actively managing its expenses, with a focus on preparing for potential commercialization of its products. The total employee headcount remains stable, supporting ongoing research and development efforts.

Looking ahead, Mereo BioPharma anticipates that it will continue to incur losses as it seeks to advance its product candidates through clinical trials and regulatory approvals. The company is exploring various funding options, including public and private equity, to support its operations and development plans. While it has made strides in its clinical programs, the path to profitability remains uncertain, and Mereo will need to secure additional funding to sustain its operations and achieve its strategic objectives.